Summary K562 leukaemia cells were selected for resistance using 0.5 tiLM etoposide (VP-16). Cloned K/VP.5 cells were 30-fold resistant to growth inhibition by VP-16 and 5-to 13-fold resistant to m-AMSA, adriamycin and mitoxantrone. K/VP.5 cells did not overexpress P-glycoprotein; VP-16 accumulation was similar to that in K562 cells. VP-16-induced DNA damage was reduced in cells and nuclei from K/VP.5 cells compared with K562 cells. Topoisomerase II protein was reduced 3-to 7-fold and topoisomerase IIa and topoisomerase IIP mRNAs were each reduced 3-fold in resistant cells. After drug removal, VP-16-induced DNA damage disappeared 1.7 times more rapidly and VP-16-induced DNA-topoisomerase II adducts dissociated 1.5 times more rapidly in K/VP.5 cells than in K562 cells. ATP (I mM) was more effective in enhancing VP-16-induced DNA damage in nuclei isolated from sensitive cells than in nuclei from resistant cells. In addition, ATP (0.3-5 mM) stimulated VP-16-induced DNA-topoisomerase II adducts to a greater extent in K562 nuclei than in K/VP.5 nuclei. Taken together, these results indicate that resistance to VP-16 in a K562 subline is associated with a quantitative reduction in topoisomerase II protein and, in addition, a distinct qualitative alteration in topoisomerase II affecting the stability of drug-induced DNA-topoisomerase II complexes.
DNA topoisomerase II (topoisomerase II) is a nuclear matrix-associated DNA-binding protein responsible for transient cleavage of DNA, allowing the passage of DNA double strands through formed DNA breaks to relieve torsional stress during replication and transcription (Wang, 1985; Liu, 1989; Osheroff, 1989) . Topoisomerase II also allows for separation of daughter DNA strands during mitosis and is thought to play a role in recombinational events (Wang, 1985) . Topoisomerase II is a target for a number of clinically effective antineoplastic agents including m-AMSA, doxorubicin, mitoxantrone, VM-26 and VP-16 (Chen et al., 1984; Tewey et al., 1984a,b; Zwelling, 1985; Minford et al., 1986; Zhang, 1990) . These drugs interfere with topoisomerase II activity by stabilising topoisomerase II/DNA binding and strand breakage, a result of blockade of the religation/ resealing reaction which follows topoisomerase 1I-mediated strand breakage (Chen et al., 1984; Nelson et al., 1984) . Drug resistance associated with alterations in the level, activity and/or phosphorylation state of topoisomerase II has been reported in both murine and human malignant cell lines selected for resistance in the presence of topoisomerase II inhibitors (Glisson et al., 1986; Odaimi et al., 1986; Pommier et al., 1986a,b; Danks et al., 1987; 1988; Drake et al., 1987; Per et al., 1987; Davies et al., 1988; Ferguson et al., 1988; Deffie et al., 1989; Harker et al., 1989; Roberts et al., 1989; Zwelling et al., 1989; Fernandes et al., 1990; Matsuo et al., 1990; Charcosset et al., 1991; Cole et al., 1991; Friche et al., 1991; Long et al., 1991; Sugawara et al., 1991; Takano et al., 1991; Webb et al., 1991; Patel & Fisher, 1993; Sullivan et al. 1993) . In several resistant cell lines, quantitative reduction of topoisomerase II expression has been correlated with the level of drug resistance in the absence of alterations of drug transport and may represent the major or sole determinant for resistance Cole et al., 1991; Long et al., 1991; Takano et al., 1991; Webb et al., 1991) . In other cell lines selected for resistance in the presence of VP-16, VM-26, anthracyclines or mitoxantrone, there is not only reduced topoisomerase II expression but also reduced drug accumulation, often (but not always) correlated with amplification of the mdrl gene and overexpression of the 150-180 kDa Pglycoprotein drug efflux pump (Ferguson et al., 1988; Deffie et al., 1989; Matsuo et al., 1990; Politi et al., 1990; Friche et al., 1991; Long et al., 1991; Kamath et al., 1992; de Jong et al., 1993) . Qualitative alterations in topoisomerase II activity have also been reported (Danks et al., 1988; Zwelling et al., 1989; Sullivan et al., 1989; 1993) in cell lines selected for resistance in the presence of topoisomerase II inhibitors (Gupta et al., 1983; Beran & Anderson, 1987; Danks et al., 1987; Sullivan et al., 1993) In several of these resistant human leukaemia cell lines point mutations have been identified within or near nucleotide-binding consensus sequences of the topoisomerase II gene (Bugg et al., 1991; Hinds et al., 1991; Lee et al., 1992; Danks et al., 1993; Chan et al., 1993) . Point mutations have also been identified near the active-site tyrosine 804 in resistant cell topoisomerase IIa obtained from CCRF CEM cells selected for resistance in the presence of VM-26 or VP-16 (Danks et al., 1993; Patel & Fisher, 1993) . In resistant cell lines exhibiting qualitative changes in topoisomerase II activity there are neither quantitative alterations in topoisomerase II expression nor changes in drug accumulation or overexpression of Pglycoprotein. Thus, stable resistance to topoisomerase II inhibitors can be manifest as (1) altered topoisomerase II expression alone or (2) together with the P-glycoprotein multiple drug resistance phenotype or (3) as a result of a mutation(s) resulting in a qualitative change in topoisomerase II activity.
In this paper, we describe a subline of human leukaemia K562 cells selected for resistance in the presence of VP-16 which has no alterations in drug accumulation compared with sensitive K562 cells. These stably resistant K/VP. (Norman & Thompson, 1977 For drug accumulation studies, K562 and K/VP.5 cells were suspended in a pH 7.4 buffer (buffer L) of 110 mM sodium chloride, 5 mM potassium chloride, 1 mM magnesium chloride, 5 mM sodium dihydrogen phosphate, 25 mM 4-(2-hydroxy-ethyl)-1-piperazineethanesulphonic acid and 10 mM glucose, at a final concentration of 0.5 x I07 cells ml-'. Cells were stirred in specially designed flasks by revolving Teflon paddles in a 37°C water bath, as described previously (Yalowich, 1987 (Yalowich & Goldman, 1984 Isolated nuclei were prepared by washing '4C-labelled whole cells in an ice-cold buffer A (pH 6.4) containing 1 mM potassium dihydrogen phosphate, 5 mM magnesium chloride, 150 mM sodium chloride and 1 mM EGTA (Filipski & Kohn, 1982) . The cells were resuspended in 1 ml of this buffer, and an additional 9 ml of buffer A containing 0.3% Triton X-100 was added to lyse the cells. After incubation on ice for 30 min, 40 ml of buffer A was added, and nuclei were pelleted by centrifugation at 1,000 r.p.m. for 10 min in an IEC model HN-SII tabletop centrifuge. Nuclei density was adjusted to 1 x 106 ml-' in cold buffer. After warming at 37C for 15 min, the nuclei were treated with VP-16 and other agents in the presence or absence of 1 mM ATP and processed for measurement of DNA damage as described below.
Drug-mediated DNA damage was assessed using the alkaline elution technique for high-frequency single-strand breaks (Kohn et al., 1976 Determination of DNA-protein cross-link (DPC) frequency was accomplished as previously described (Ross et al., 1979) . Aliquots of ['4C]thymidine-labelled K562 and K/ VP.5 cells (5 x 10 ml-') or nuclei (1 x 106 ml-'), drugtreated or controls, were irradiated on ice with 3,000 rad prior to elution, as were internal control 3H-labelled L1210 cells. Cells or nuclei were layered onto polyvinylchloride-acrylic co-polymer filters (Metricel DM-800; Gelman Sciences) along with 7.5 x 105 internal control cells, and lysed with 5 ml of a solution of 0.2% Sarkosyl, 2 M sodium chloride, 0.04 M disodium EDTA, pH 10, which was allowed to flow through the filters by gravity, as was a 3 ml addition of 0.04 M disodium EDTA, pH 10. DNA was eluted with tetrapropylammonium hydroxide, pH 12.1, at a flow rate of 0.035 ml min-'. Fractions were collected at 90 min intervals for 12 h. DPC frequencies were calculated according to the bound-to-one terminus model (Ross et al., 1979) :
where ro and r are the fractional filter retentions of DNA extrapolated to zero time from [14C]thymidine-labelled control and drug-treated cells (or nuclei) respectively and PB is the radiation dose administered (3,000 rad). The greater the DNA retention of drug-treated cells relative to controls, the greater the DPC frequency.
DNA topoisomerase II-DNA covalent complex formation assay-intact cells and nuclei Mid-log cells (1.5-2.0 x IO cells ml-') were labelled overnight with 0.5 itCi ml-' [methyl-3H]thymidine (0.5 Ci mmol-') and 0.1ILCi mlh-[U-_4C]leucine (318 mCi mmol-') in DMEM containing 5% FBS. Cells were then pelleted and resuspended in fresh DMEM/5% FBS and incubated for 1 h at 37°C. For experiments measuring the stability of topoisomerase II-DNA covalent complexes after VP-16 removal, cells were washed, resuspended in buffer L and equilibrated to 37°C. VP-16 was added to 20-200 lM and incubation continued for an additional 15 min at 37C. Cells were pelleted for 90 s at 2,400 g, washed with ice-cold buffer L and repelleted. Cells were resuspended to 1 x 106mI-in L buffer at 37°C. At selected intervals, 1 x 106 cells were removed and added to 10 ml of ice-cold PBS and held on ice until all time points were collected. Cells were pelleted, lysed, cellular DNA sheared and protein-DNA complexes precipitated with SDS and potassium chloride as described by Zwelling et al. (1989) . For experiments examining the effect of ATP on VP-16-induced stabilisation of topoisomerase II-DNA cleavable complexes, nuclei were isolated from cells as described above and adjusted to 2 x 106 nuclei ml1' in buffer A (pH 7.4) containing 0.5 mM ATP. After prewarming at 37°C for 5 min, 200 tLM VP-16 or 0.4% DMSO (control) was added and incubation continued at 37°C for an additional 15 min. Nuclei were pelleted, lysed, cellular DNA sheared and complexes precipitated with SDS-potassium chloride exactly as for whole cells.
Topoisomerase II catalytic activity Topoisomerase II-containing extracts of nuclei were prepared from 1-2 x 108 K562 and K/VP.5 cells as previously described (Danks et al., 1988) . When the aqueous volume contributed by the nuclei is taken into consideration, the final sodium chloride concentration of the nuclear extracts varied between preparations from 0.7 to 0.85 M. Crithidia fasiculata was labelled with 8 ZCi ml-' [methyl-3H]thymidine and kinetoplast mitochondrial DNA (kDNA) isolated as previously described (Sahai & Kaplan, 1986) . Topoisomerase II catalytic activity was measured by decatenation of kDNA (Sullivan et al., 1989) . Each 40 IlI assay contained 50 mM Tris (pH 7.5), 85 mM potassium chloride, 10 mM magnesium chloride, 0.5 mM DTT, 0.5 mM disodium EDTA, 30 yg ml-' BSA, 0-1 mM ATP, 0-100MM VP-16 (in DMSO), 1 tg (10,000 c.p.m.) of 3H-labelled kDNA and 0-3 tig of nuclear extract topoisomerase II from K562 or K/VP.5 cells. After incubation at 30°C for 30 min, reactions were stopped by addition of 10 ptl of 2.5% SDS and were then centrifuged for 15 min at 8,000 g at 25°C. Duplicate 10 gl samples from each tube were counted in a liquid scintillation spectrometer in 3.5 ml of Ecolite (ICN Biochemicals, Irvine, CA, USA). Decatenation was quantitated subsequent to subtraction of counts found in DMSO controls in the absence of nuclear extract topoisomerase II.
Western blots of cell lysates Lysates from 2-5 x 106 K562 or K/VP.5 cells were prepared by the addition of an equal volume of 2 x gel loading buffer (0.1 M Tris-HCl, pH 6.8, 20% glycerol, 2% SDS, 0.5 M P-mercaptoethanol). Lysates were boiled for 5 min, sonicated to reduce viscosity and protein content determined using the BioRad protein assay. Samples containing 10 jig were electrophoresed through 6% SDS-polyacrylamide gel (Laemmli, 1970) and electroblotted at 400 mA overnight to nitrocellulose (Towbin et al., 1979 ) using a Hoefer (San Franscisco, CA, USA) Transfor apparatus. Blots were incubated with human topoisomerase II-specific rabbit antiserum, IID3 (from L.F. Liu), affinity-purified topoisomerase IIa-specific antibody FHD22 or affinity-purified topoisomerase IIP-specific antibody FHD21 (Chung et al., 1989) . The affinity-purified, isoform-specific antibodies were provided by F.H. Drake (SmithKline Beecham). Bound antibodies were detected using alkaline phosphatase-conjugated goat anti-rabbit IgG and the ProtoBlot Western Blot AP System of Promega Biotech (Madison, WI, USA). Levels of topoisomerase II were quantitated by scanning positive films of photographed blots using a Visage 110 image analyser (Ann Arbor, MI, USA).
Northern blot analysis of cellular RNAs Total cellular RNA was isolated from 1-2 x 108 K562 and K/VP.5 cells (Chomczynski & Sacchi, 1987) . RNA (10 fig) was electrophoresed through 1.2% agarose gels containing 0.3 M formaldehyde, 40 mM 3-(N-morpholono)propane sulphonic acid (MOPS) pH 7.0, 10 mM sodium acetate trihydrate, 1 mM EDTA, transferred to Nytran (Schleicher & Schuell, Keene, NH, USA) by capillary blotting overnight, baked for 2 h at 80°C and hybridised using standard techniques (Maniatis et al., 1982) . Specific RNAs were detected by autoradiography at -70°C using intensifying screens and Kodak XAR-5 X-ray film.
Probe synthesis and labelling The human topoisomerase IIo cDNA probe (ZI169) contained in the plasmid pC15 was provided by L.F. Liu. A human topoisomerase II3 cDNA probe, synthesised by polymerase chain reaction (PCR) amplification using topoisomerase Ilp-specific primers, was provided by D.P. Suttle (St Jude Children's Research Hospital, Memphis, TN, USA). The 12-microglobulin cDNA probe in plasmid P132m was provided by K.B. Tan. Cloned inserts were removed from plasmids pC15 and P12m by digestion with restriction enzymes and isolation on agarose gels. cDNA fragments were used as templates for probe synthesis using Klenow fragment, [_-32P]dCTP (3,000 Ci mmol-') and random primer initiation (Feinberg & Vogelstein, 1983) .
Results
Drug accumulation and growth-inhibitory effects in sensitive and resistant cells The K/VP.5 subline is 30-fold resistant to the 48 h growthinhibitory effects of the selecting agent VP-16, and equally cross-resistant to VM-26 (Table I ). In addition, there was lower (5-to 13-fold) cross-resistance to m-AMSA, adriamycin and mitoxantrone, three other agents that are known to inhibit topoisomerase II. K/VP.5 cells cultured in the absence of VP-16 have maintained this level of resistance for 2 years. In contrast, K/VP.5 cells were not cross-resistant to the microtubule inhibitors vincristine, vinblastine and podophyllotoxin, the antimetabolite arabinosyl cytosine or to the DNA topoisomerase I inhibitor camptothecin (Table I ). Figure 1 indicates that the steady-state concentrations of in K/VP.5 cells were slightly higher than in parental K562 cells when cells were exposed to 2.5-2011mM [3H]VP-16. These results are consistent with those previously reported (Beran & Anderson, 1987) , in which accumulation of m-AMSA was slightly increased in HL-60 cells selected for resistance in the presence of m-AMSA. Accounting for intracellular water content (Yalowich & Goldman, 1984) (Yalowich, 1987 Topoisomerase II levels: Western blot analysis The amount of topoisomerase II in whole-cell lysates and in 0.8 M sodium chloride nuclear extracts from K562 and K/ VP.5 cells was determined by Western blotting utilising rabbit IID3 antiserum to human DNA topoisomerase II ( Figure  5 ). Two bands were observed in the lane containing purified topoisomerase II from P388 leukaemia cells as well as in lanes corresponding to K/VP.5 nuclear extracts. The molecular weights of these bands were 170 ± 3 kDa and 179 ± 3 kDa (mean ± s.e.; n = 5), corresponding to previously characterised topoisomerase IIa and topoisomerase II,B isoforms of this enzyme respectively (Chung et al., 1989; Drake et al., 1989 
10 50 (topoisomerase II,B) showed much less staining in both sensitive and resistant cell lysates and nuclear extracts and could not be accurately quantitated. However, we independently quantitated levels of each topoisomerase II isoform by probing Western blots (not shown) of whole-cell lysates with polyclonal antibodies that specifically recognise either topoisomerase Iat (antibody FHD22) or topoisomerase IIP (antibody FHD21). Results from three independent blots showed that topoisomerase IIha and topoisomerase Ip were reduced 5.6-± 1.6-fold and 2.7-± 0.1-fold respectively (mean ± s.e.) in K/VP.5 compared with K562 cells.
Topoisomerase II expression: Northern blot analysis of total RNA Using the human topoisomerase II cDNA probe (ZI169) and total cellular RNA isolated from K562 and K/VP.5, we observed a 2.9-fold reduction in expression of 6.2 kb topoisomerase IIa RNA in K/VP.5 compared with parental K562 cells (Figure 6 ). Co-hybridisation of a 132-microglobulin (Table II ). In contrast, when the VP-16 concentration was increased to 100;1m to achieve a similar SSB frequency in K/VP.5 nuclei, ATP enhanced drug-induced DNA damage less than 2-fold. Similarly, ATP-mediated enhancement of VP-16-induced DNA-protein cross-linking was significantly less in resistant K/VP.5 than in sensitive K562 nuclei (Table II) . Since topoisomerase II catalytic activity is dependent on binding (but not hydrolysis) of ATP (Osheroff, 1989) , and since ATP is known to stimulate VP-16-, m-AMSA-, ellipticine-and 5-iminodaunorubicin-induced DNA damage in isolated nuclei from L1210 cells (Glisson et and K/VP.5 cells respectively (P = 0.21).
inhibition of catalytic decatentation using nuclear extract preparations from sensitive and resistant cells (Figure 11 ).
Discussion
The results presented in this study indicate that resistance to (Long et al., 1991; Sugawara et al., 1991) or stepwise increases in drug exposure (Ferguson et al., 1988; Matsuo et al., 1990; de Jong et al., 1993) (Cleveland & Yen, 1989 . In addition, no change in topoisomerase II transcription rate was observed in K/VP.5 compared with K562 cells (Danks et al., 1989 ) and suggest a mutation in or near ATP-binding domains of topoisomerase II consistent with identified topoisomerase II mutations in several other resistant cell lines (Bugg et al., 1991; Hinds et al., 1991; Lee et al., 1992; Chan et al., 1993; Danks et al., 1993) However, topoisomerase II cDNA sequence analysis has revealed no changes in the region which includes consensus nucleotide-binding domains (nucleotides 1134-1597) comparing K562 and K/VP.5 cells (Ritke et al., submitted) . In addition, single-strand conformational polymorphism analysis of topoisomerase II cDNA from K/VP.5 cells has uncovered no evidence of mutations (Ritke et al., submitted) . Single-strand conformation polymorphism analysis has been used previously to identify point mutations in topoisomerase II cDNA from drug-resistant cell lines (Danks et al., 1993) . These results suggest that, despite the stable biochemical changes in K/VP.5 topoisomerase II which implicate mutations in the gene coding for this enzyme, there may be other genetic changes in resistant cells that affect topoisomerase II function. Sequence analysis of the entire coding sequence of K/VP.5 and K562 topoisomerase II cDNA is under way and will definitively reveal whether a point mutation(s) in K/VP.5 cells is related to qualitative and/or quantitative topoisomerase II alterations documented in the present work.
A second target for genetic alteration of VP-16-selected K/VP.5 cells may be a regulator, effector or co-factor of topoisomerase II. Topoisomerase II has been shown to be phosphorylated in intact cells at serine and threonine residues (Saijo et al., 1990; Kroll & Rowe, 1991; Cardenas et al., 1992) and in vitro serves as a substrate for casein kinase II, protein kinase C and p34cdc2 kinase (Ackerman et al., 1985; 1988; Sahyoun et al., 1986; Cardenas et al., 1992; Devore et al., 1992; Corbett et al., 1993) . In addition, the activity and degree of phosphorylation of topoisomerase II has been found to increase during cell cycle progression from GI to G2-M phase (Heck et al., 1989; Woessner et al., 1991; Saijo & Enomoto, 1992) . These studies suggest a protein kinase as a candidate topoisomerase II co-factor and a mutational target in resistant K/VP.5 cells. Mutation and subsequent altered activity of a protein kinase that phosphorylates topoisomerase II might reduce the stability of this enzyme, resulting in a decreased level of protein in resistant cells. A change in topoisomerase II phosphorylation in resistant cells might also influence ATP binding/hydrolysis and affect catalytic activity, as has recently been demonstrated using Drosophila topoisomerase II (Corbett et al., 1993) . Altered phosphorylation of topoisomerase II in resistant cells may change the stability of topoisomerase II binding to DNA such that VP-16 stabilisation of the protein-DNA complex is compromised. Recent studies in this laboratory indicate that topoisomerase II phosphorylation is reduced at least 2-fold in K/VP.5 compared with parental K562 cells (Ritke et al., submitted) . Therefore, altered topoisomerase II phosphorylation in K/VP.5 cells correlates with decreased VP-16-induced topoisomerase II-DNA binding stability in these resistant cells (Figure 8) .
Based on studies presented here, we conclude that selection for a low level of resistance to VP-16 resulted in a quantitative reduction of topoisomerase II expression as well as distinct qualitative changes affecting VP-16-induced stability of topoisomerase II-DNA binding. The multiple stable phenotypic changes exhibited by the novel K/VP.5 cell line provide an opportunity to increase our understanding of the post-transcriptional and/or post-translational modifications in DNA topoisomerase II which regulate its activity in acquired drug resistance. (1988) . Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to 27, [8861] [8862] [8863] [8864] [8865] [8866] [8867] [8868] [8869] 
